natgillin/translations-raw huggingface dataset:
¾ The scope of the referral was to discuss the benefit/risk of the different dosage recommendations for newborns, especially regarding the differentiation of newborns up to 14 days of age and from 15 up to 27 days of age and regarding the use of dose in excess of 50 mg/kg/day ¾ The Summary of Products Characteristic, labelling and package leaflet proposed by the applicant has been assessed based on the documentation submitted and the scientific discussion within the Committee. 
¾ Obseg napotitve je bila razprava o razmerjih med koristmi in tveganji izhajajočih iz različnih priporočil za odmerjanje pri novorojencih, zlasti glede razlikovanja novorojencev, starih do 14 dni in od 15 do 27 dni, in glede uporabe odmerkov, večjih od 50 mg/kg/dan,
Do not use Ceftriaxone Tyrol Pharma 2g if: 
Ceftriaxone Tyrol Pharma 2 g ne uporabljajte če:
Pancreatitis (see section 4.4). 
Vnetje trebušne slinavke (glejte poglavje 4.4).
Do not use Ceftriaxone Tyrol Pharma 1g if: 
Ceftriaxone Tyrol Pharma 1 g ne uporabljajte če:
General disorders and administration site conditions Common: 
Splošne težave in težave na mestu dajanja
Patients with an impaired renal function have an increased excretion of ceftriaxone into the bile. 
Pri bolnikih z zmanjšanim delovanjem ledvic je izločanje ceftriaksona v žolč večje.
Phlebitis following intravenous administration. 
Flebitis po intravenskem dajanju.
Newborn babies (up to 14 days old) 20-50mg for each kg of body weight once a day, injected into a vein More than 50mg per kg must not be given, even in severe infections. 
Novorojenci (stari od 0 do 14 dni): 20-50 mg na kg telesne teže intravensko enkrat na dan (v 24-urnih presledkih).
Only clear solutions should be used. 
Uporabiti se sme le bistre raztopine.
Each 2 g bottle contains 2 g ceftriaxone (as hydrated disodium). 
Vsaka 2 g steklenička vsebuje 2 g ceftriaksona (v obliki hidratirane dinatrijeve soli).
Method and route of administration of Ceftriaxone Tyrol Pharma 2 g powder for solution for infusion 
Metoda in način dajanja Ceftriaxone Tyrol Pharma 2 g praška za raztopino za infundiranje
Ceftriaxone Tyrol Pharma 1g powder for solution for infusion or injection (ceftriaxone sodium) 
Ceftriaxon Tyrol Pharma 1 g prašek za raztopino za infundiranje ali injiciranje (ceftriakson natrij)
Powder for solution for infusion 
Prašek za raztopino za infundiranje
Ceftriaxone Tyrol Pharma 2g, powder for solution for infusion (ceftriaxone sodium) 
Ceftriaxon Tyrol Pharma 2 g prašek za raztopino za infundiranje (ceftriakson natrij)
How to use Ceftriaxone Tyrol Pharma 2g 
Kako uporabljati Ceftriaxone Tyrol Pharma 2 g
None. 
Redki
The content of the infusion bottle is dissolved in 40 ml of one of the following calcium-free infusion solutions by swirling, resulting in a concentration of 0.05 g/ml: sodium chloride solution 0.9 %, sodium chloride (0.45 %) and glucose (2.5 %) solution, glucose solution 5 % or 10 %, dextran 6 % in glucose solution 5 %, hydroxyethylen starch solution 6 
Vsebino viale se z vrtinčenjem raztopi v 40 ml ene izmed naslednjih infuzijskih raztopin, ki ne vsebujejo kalcija, pri čemer dobimo koncentracijo 0,05 g/ml: 0,9% raztopina natrijevega klorida, raztopina natrijevega klorida (0,45%) in glukoze (2,5%), 5% ali 10% raztopina glukoze, 6% dekstran v 5% raztopini glukoze, 610% raztopina hidroksietilen škroba.
Intravenous infusion (infusion into a vein) Ceftriaxone Tyrol Pharma 1g for infusion is administered as a short intravenous infusion. 
Ceftriaxone Tyrol Pharma 1 g za infundiranje se daje v obliki kratke intravenske infuzije.
How to use Ceftriaxone Tyrol Pharma 1g 
Kako uporabljati Ceftriaxone Tyrol Pharma 1 g
Method and route of administration of Ceftriaxone Tyrol Pharma 1g powder for solution for injection/infusion 
Metoda in način dajanja Ceftriaxone Tyrol Pharma 1 g praška za raztopino za injiciranje / infundiranje
20-80mg for each kg of body weight once a day, injected into a vein More than 80mg per kg must not be given, even in severe infections -except in meningitis. 
• Več kot 80 mg na kg se ne sme dajati, niti pri hudih okužbah - razen pri meningitisu.
The ready-to-use solutions are pale yellow to amber. 
Za uporabo pripravljene raztopine so bledo rumene do rumenkasto rjave barve.
It is bactericidal against a wide range of Gram-positive and Gram-negative bacteria by inhibiting the mucopeptide synthesis in the bacterial cell wall. 
Z zaviranjem sinteze mukopeptidov v bakterijski celični steni učinkuje baktericidno proti širokem spektru grampozitivnih in gramnegativnih bakterij.
In particular, tell your doctor or pharmacist if you are using: other antibiotics for treating infections like aminoglycosides oral contraceptive pills. 
• druge antibiotike za zdravljenje okužb, kot so na primer aminoglikozidi
Precipitations of ceftriaxone - calcium salt have been observed in lungs and kidneys of these dead preterm newborns. 
V pljučih in ledvicah teh umrlih prezgodaj rojenih novorojencev so opazili oborino ceftriakson-kalcijeve soli.
- aminoglycosides (when given concurrently, these preparations must be administered separately) - Ceftriaxone Tyrol Pharma 2g must not be administered in the same syringe as other antibiotics or other bactericidal agents. 
- Ceftriaxone Tyrol Pharma 2 g se nikoli ne sme dati v isti brizgi kot druge antibiotike ali druga baktericidna sredstva.
- aminoglycosides (when given concurrently, these preparations must be administered separately) - Ceftriaxone Tyrol Pharma 1g must not be administered in the same syringe as other antibiotics or other bactericidal agents. 
- Ceftriaxone Tyrol Pharma 1 g se nikoli ne sme dati v isti brizgi kot druge antibiotike ali druga baktericidna sredstva.
PHARMACEUTICAL FORM Powder for solution for infusion Almost white or yellowish, crystalline dry powder 
Skoraj bel ali rumenkast kristalen suh prašek
Colics occurred very rarely in the presence of nephropathy or cholelithiasis when using high doses administered more frequently and more rapidly than recommended. 
Pri uporabi velikih odmerkov, ki so jih bolniki dobivali pogosteje in hitreje kot pa je priporočeno, so se zelo redko pojavili črevesni krči ob nefropatiji ali žolčnih kamnih.
What Ceftriaxone Tyrol Pharma 1g is and what it is used for Ceftriaxone is an antibiotic. 
Kaj je Ceftriaxone Tyrol Pharma 1 g in za kaj se uporablja
BATCH NUMBER Lot 
ŠTEVILKA SERIJE Št. serije
Intravenous infusion (infusion into a vein) Ceftriaxone Tyrol Pharma 2g is administered as a short intravenous infusion. 
Ceftriaxone Tyrol Pharma 2 g se daje v obliki kratke intravenske infuzije.
Take special care with Ceftriaxone Tyrol Pharma 2g if: 
Pri uporabi Ceftriaxone Tyrol Pharma 2 g morate biti posebno pozorni če:
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING Vial 
PODATKI, KI SE NAHAJAJO NA STIČNI OVOJNINI Viala
What Ceftriaxone Tyrol Pharma 2g looks like and contents of the pack 
Kaj je Ceftriaxone Tyrol Pharma 2 g in za kaj se uporablja
Rare side effects (affects less than 1 out of 1,000 people) severe cramps in the belly (caused by inflammation of the pancreas) Gall stones in adults drops in the numbers of white blood cells (sometimes severe with increased risk of severe infection) 
• zmanjšanje števila belih krvničk (včasih zelo izrazito, s povečanjem tveganja, da pride do hude okužbe)
Absorption 
Resorbcija
The following adverse reactions, that reverse spontaneously or after treatment discontinuation, have been observed in association with ceftriaxone use. 
V povezavi z uporabo ceftriaksona so opazili naslednje neželene učinke, ki so prenehali sami od sebe ali po prenehanju zdravljenja.
Take special care with Ceftriaxone Tyrol Pharma 1g if: 
Pri uporabi Ceftriaxone Tyrol Pharma 1 g morate biti posebno pozorni če:
Before you use Ceftriaxone Tyrol Pharma 1g 
Kaj morate vedeti pred uporabo Ceftriaxone Tyrol Pharma 1 g
Before you use Ceftriaxone Tyrol Pharma 2g 
Kaj morate vedeti pred uporabo Ceftriaxone Tyrol Pharma 2 g
Infections and Infestations Uncommon: 
Profilaksa ob operativnih posegih:
Date of first authorisation: 15 July 1998 Date of latest renewal: 15 July 2008 
Datum zadnjega podaljšanja dovoljenja za promet: 15. julij 2008
Some other medicines may influence the use of Plavix or vice versa. 
Nekatera druga zdravila lahko vplivajo na uporabo zdravila Plavix in obratno.
Do not use this medicine if you notice any visible sign of deterioration. 
Ne uporabljajte tega zdravila, če opazite vidne znake kvarjenja.
Do not give this medicine to children because it does not work. 
Otroci in mladostniki Ne dajajte tega zdravila otrokom ali mladostnikom, ker ne deluje.
ANNEX II A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
PRILOGA II A. IZDELOVALCI, ODGOVORNI ZA SPROŠČANJE SERIJE B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA
Week 2 (for boxes of 14, 28 and 84 tablets) Week 3 (for boxes of 28 and 84 tablets) Week 4 (for boxes of 28 and 84 tablets) 
Teden 2 (samo za škatle z 14, 28 in 84 tabletami) Teden 3 (samo za škatle z 28 in 84 tabletami) Teden 4 (samo za škatle z 28 in 84 tabletami)
Strada Statale 17, Km 22 67019 Scoppito (AQ) Italy 
Strada Statale 17, Km 22 67019 Scoppito (AQ) Italija
You should take Plavix for as long as your doctor continues to prescribe it. 
Zdravilo Plavix morate jemati, vse dokler vam ga vaš zdravnik predpisuje.
If you have been told by your doctor that you have an intolerance to some sugars (e.g. lactose), contact your doctor before taking this medicine. 
Če vam je zdravnik povedal, da imate intoleranco za nekatere sladkorje (npr. laktozo), se pred uporabo tega zdravila posvetujte s svojim zdravnikom.
67019 Scoppito (AQ) - Italy or 
67019 Scoppito (AQ) - Italija ali
Posology • Adults and elderly 
Odmerjanje • Odrasli in starostniki
What Plavix is and what it is used for 
Kaj je zdravilo Plavix in za kaj ga uporabljamo
• if you have had an allergy or reaction to any medicine used to treat your disease. 
• če ste imeli alergijo ali alergijsko reakcijo na katero koli zdravilo, ki ste ga jemali
Patients should be followed carefully for any signs of bleeding including occult bleeding, especially during the first weeks of treatment and/or after invasive cardiac procedures or surgery. 
Bolnike morate skrbno spremljati zaradi znakov krvavitve, vključno z okultno krvavitvijo, zlasti prve tedne zdravljenja in/ali po invazivnih kardioloških postopkih ali kirurških posegih.
Taste disturbances, ageusia 
Motnje okusa, agevzija
Patients should be told that it might take longer than usual to stop bleeding when they take clopidogrel (alone or in combination with ASA), and that they should report any unusual bleeding (site or duration) to their physician. 
Bolniki morajo biti obveščeni, da je lahko čas, potreben za zaustavitev krvavitve, daljši kot ponavadi, ko jemljejo klopidogrel (sam ali v kombinaciji z ASA) in da morajo poročati svojemu zdravniku o kakršnikoli neobičajni krvavitvi (mesto ali trajanje).
You should have been told that ‘oral anticoagulants' are more effective than acetylsalicylic acid or the combined use of Plavix and acetylsalicylic acid for this condition. 
Povedati so vam morali, da so "peroralni antikoagulanti" pri tej motnji učinkovitejši kot acetilsalicilna kislina ali kombinirana uporaba zdravila Plavix in acetilsalicilne kisline.
• if you have kidney or liver disease. 
• če imate ledvične ali jetrne bolezni
• if you have had a clot in an artery of your brain (ischaemic stroke) which occurred within the last seven days. 
• če ste imeli strdek v možganski arteriji (ishemična kap), ki se je pojavil v zadnjih sedmih dneh
Other medicinal products: A number of other clinical studies have been conducted with clopidogrel and other concomitant medicinal products to investigate the potential for pharmacodynamic and pharmacokinetic interactions. 
Številne druge klinične študije so izvedli s klopidogrelom in drugimi sočasno danimi zdravili, da bi proučili potencial za farmakodinamične in farmakokinetične interakcije.
As no clinical data on exposure to clopidogrel during pregnancy are available, it is preferable not to use clopidogrel during pregnancy as a precautionary measure. 
Ker kliničnih podatkov o izpostavljenosti klopidogrelu med nosečnostjo ni, je kot previdnostni ukrep zaželeno, da se klopidogrela v nosečnosti ne uporablja.
In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both groups. 
V študiji COMMIT je bil skupni delež večjih necerebralnih krvavitev ali cerebralne krvavitve nizek in podoben v obeh skupinah .
Boosted anti-retroviral therapy (ART): HIV patients treated with boosted anti-retroviral therapies (ART) are at high risk of vascular events. 
Okrepljeno protiretrovirusno zdravljenje (ART- anti-retroviral therapies): Bolniki s HIV, zdravljeni z okrepljenimi ART, imajo veliko tveganja za žilne dogodke.
Other medicines and Plavix 
Druga zdravila in zdravilo Plavix
Manufacturers: 
Izdelovalec:
- If you have a medical condition that is currently causing bleeding such as a stomach ulcer or bleeding within the brain. 
- če imate zdravstveno stanje, ki trenutno povzroča krvavitev, kot je rana na želodcu ali krvavitev v možganih.
Bleeding time prolonged, neutrophil count decreased, platelet count decreased * Information related to clopidogrel with frequency “not known”. 
Podaljšan čas krvavitve, zmanjšano število nevtrofilcev, zmanjšano število trombocitov * Podatki se nanašajo na klopidogrel s pogostnostjo “neznani”.
- If you suffer from severe liver disease. 
- če imate hudo jetrno obolenje.
Although the clinical relevance of these findings is uncertain, there have been spontaneous reports of HIV-infected patients treated with ritonavir boosted ART, who have experienced re-occlusive events after de-obstruction or have suffered thrombotic events under a clopidogrel loading treatment schedule. 
Čeprav je klinični pomen teh izsledkov negotov, so bila zabeležena spontana poročila bolnikov, okuženih s HIV in zdravljenih z okrepljenim ART z ritonavirjem, ki so se jim po odstranitvi obstrukcije pojavile ponovne zapore, ali pa so se jim trombotični dogodki pojavili med shemo polnilnega zdravljenja s klopidogrelom.
It also contains: hydrogenated castor oil and lactose. 
Vsebuje tudi: hidrogenirano ricinusovo olje in laktozo.
• Hypersensitivity to the active substance or to any of the excipients listed in section 2 or section 
• Preobčutljivost za zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju 2 ali v poglavju 6.1.
Microcrystalline cellulose Hydrogenated castor oil Low substituted hydroxypropylcellulose 
mikrokristalna celuloza hidrogenirano ricinusovo olje delno substituirana hidroksipropilceluloza
Average platelet inhibition can be decreased with concomitant use of clopidogrel and ritonavir. 
Povprečna inhibicija trombocitov se lahko med sočasno uporabo klopidogrela in ritonavirja zmanjša.
In CURE, there was no excess in major bleeds with clopidogrel plus ASA within 7 days after coronary bypass graft surgery in patients who stopped therapy more than five days prior to surgery. 
V CURE število velikih krvavitev s klopidogrelom in ASA ni bilo prekoračeno v 7 dneh po koronarni premostitveni operaciji pri bolnikih, ki so prenehali z zdravljenjem več kot 5 dni pred kirurškim posegom .
• Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. 
• odraslih bolnikih z miokardnim infarktom (od nekaj dni do manj kot 35 dni), ishemično kapjo (od 7 dni do manj kot 6 mesecev) ali dokazano periferno arterijsko boleznijo.
Your doctor should have prescribed Plavix plus acetylsalicylic acid if you cannot take ‘oral anticoagulants' and you do not have a risk of major bleeding. 
Zdravnik naj bi vam predpisal zdravilo Plavix skupaj z acetilsalicilno kislino, če ne morete prejemati "peroralnih antikoagulantov", ali če nimate tveganja za večjo krvavitev.
If you become pregnant while taking Plavix, consult your doctor immediately as it is recommended not to take clopidogrel while you are pregnant. 
Če med zdravljenjem z zdravilom Plavix zanosite, se takoj posvetujte s svojim zdravnikom, saj jemanje klopidogrela med nosečnostjo ni priporočljivo.
If you have experienced severe chest pain (unstable angina or heart attack), you may be prescribed Plavix in combination with acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever. 
Če ste doživeli hudo bolečino v prsih (nestabilna angina pektoris ali srčni napad), so vam morda predpisali zdravilo Plavix v kombinaciji z acetilsalicilno kislino, učinkovino, ki je prisotna v številnih zdravilih, ki se uporabljajo za lajšanje bolečine in zniževanje zvišane telesne temperature.
Experience is limited in patients with moderate hepatic disease who may have bleeding diatheses. 
Izkušnje so omejene pri bolnikih z zmerno jetrno boleznijo, ki imajo lahko hemoragično diatezo.
During non-clinical studies in rat and baboon, the most frequently observed effects were liver changes. 
V predkliničnih študijah na podganah in pavijanih, so bile jetrne spremembe najpogosteje opaženi učinek.
Detailed information on this medicinal product is available on the website of the European Medicines Agency: http://www.ema.europa.eu/ 
DATUM ZADNJE REVIZIJE BESEDILA Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila : http://www.ema.europa.eu/.
Serum sickness, anaphylactoid reactions, cross-reactive drug hypersensitivity among thienopyridines (such as ticlopidine, prasugrel) (see section 4.4)*, insulin autoimmune syndrome, which can lead to severe hypoglycemia, particularly in patients with HLA DRA4 subtype (more frequent in the Japanese population)* 
Serumska bolezen, anafilaktoidne reakcije, navzkrižna preobčutljivost med tienopiridini (kot sta tiklopidin in prasugrel) (glejte poglavje 4.4)*, avtoimuni inzulinski sindrom, ki lahko vodi v resno hipoglikemijo, še posebej pri bolnikih s HLA DRA4 podtipom (pogostejši v japonski populaciji)*
The recommended dose, including for patients with a condition called ‘atrial fibrillation' (an irregular heartbeat), is one 75 mg tablet of Plavix per day to be taken orally with or without food, and at the same time each day. 
Priporočeni odmerek, vključno za bolnike, ki imajo bolezensko stanje, imenovano "atrijska fibrilacija" (nepravilen srčni utrip), je ena 75 mg tableta zdravila Plavix na dan, ki jo lahko vzamete s hrano ali brez nje; odmerek morate jemati vsak dan ob istem času.
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Plavix. 
Če ste noseči ali mislite, da ste noseči, morate o tem obvestiti svojega zdravnika ali farmacevta, preden vzamete zdravilo Plavix.
As a precautionary measure, breast-feeding should not be continued during treatment with Plavix. 
Iz varnostnih razlogov naj se z dojenjem med zdravljenjem z zdravilom Plavix ne nadaljuje.
Delpharm Dijon 6, Boulevard de l'Europe F-21800 Quétigny France 
Delpharm Dijon 6, Boulevard de l'Europe F-21800 Quétigny Francija
If you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking Plavix. 
Če menite, da se karkoli od navedenega nanaša na vas, ali če ste kakorkoli v dvomih, se posvetujte s svojim zdravnikom, preden boste vzeli zdravilo Plavix.
Patients randomized in the ACTIVE program were those presenting with documented AF, i.e., either permanent AF or at least 2 episodes of intermittent AF in the past 6 months, and had at least one of the following risk factors: age ≥75 years or age 55 to 74 years and either diabetes mellitus requiring drug therapy, or documented previous MI or documented coronary artery disease; treated for systemic hypertension; prior stroke, transient ischaemic attack (TIA), or non-CNS systemic embolus; left ventricular dysfunction with left ventricular ejection fraction <45%; or documented peripheral vascular disease. 
V program ACTIVE so bili randomizirani bolniki, ki so imeli dokumentirano AF, tj. bodisi permanentno AF ali vsaj 2 epizodi intermitentne AF v zadnjih 6 mesecih ter vsaj enega od naslednjih dejavnikov tveganja: starost  75 let ali starost od 55 do 74 let in bodisi sladkorno bolezen, ki je zahtevala zdravljenje z zdravili, ali dokumentiran predhodni MI ali dokumentirano koronarno bolezen; zdravljenje zaradi sistemske hipertenzije; predhodno možgansko kap, tranzitorno ishemično atako (TIA) ali sistemski embolus (ne v osrednjem živčevju); disfunkcijo levega prekata z iztisnim deležem levega prekata (LVEF) < 45 %; ali dokumentirano bolezen perifernih žil.
- a planned surgery (including dental) in the next seven days. 
- nedavna huda poškodba - nedaven kirurški poseg (vključno na zobeh) - načrtovan kirurški poseg (vključno na zobeh) v naslednjih 7 dneh
The most common side effect reported with Plavix is bleeding. 
Najpogostejši neželeni učinek, o katerem so poročali z zdravilom Plavix je krvavitev.
Then, the recommended dose is one 75-mg tablet of Plavix per day as described above. 
Nato je priporočeni odmerek ena 75-mg tableta zdravila Plavix na dan, kot je opisano zgoraj.
If you forget to take Plavix 
Če ste pozabili vzeti zdravilo Plavix
Hypromellose (E464) Lactose monohydrate Triacetin (E1518) Titanium dioxide (E171) Red iron oxide (E172) 
Obloga: hipromeloza (E464) laktoza monohidrat triacetin (E1518) titanov dioksid (E171) rdeči železov oksid (E172)
Plavix contains clopidogrel and belongs to a group of medicines called antiplatelet medicinal products. 
Zdravilo Plavix vsebuje klopidogrel in spada v skupino zdravil, ki se imenujejo zaviralci agregacije trombocitov.
TOPIC (Timing Of Platelet Inhibition after acute Coronary syndrome) This randomized, open-label trial included ACS patients requiring percutaneous coronary intervention (PCI). 
Študija TOPIC (Tempiranje zavrtja trombocitov po akutnem koronarnem sindromu) To randomizirano, odprto preskušanje je vključilo bolnike z AKS, ki so potrebovali perkutano koronarno intervencijo (PKI).
If you forget to take a dose of Plavix, but remember within 12 hours of your usual time, take your tablet straightaway and then take your next tablet at the usual time. 
Če pozabite vzeti odmerek zdravila Plavix in se nanj spomnite do 12 ur po ustaljenem času, takoj vzemite tableto in nato vzemite naslednjo tableto spet ob ustaljenem času jemanja.
6, boulevard de l'Europe, F-21800 Quétigny, France or 
6, Boulevard de l'Europe, F-21800 Quétigny, Francija ali
(≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare 
Njihova pogostnost je navedena upoštevaje naslednji dogovor: pogosti (≥ 1/100, < 1/10), občasni (≥ 1/1.000, < 1/100), redki (≥ 1/10.000, < 1/1.000), zelo redki (< 1/10.000) , neznani (ni mogoče oceniti iz razpoložljivih podatkov).
If you stop taking Plavix Do not stop the treatment unless your doctor tells you so. 
Ne prekinite zdravljenja razen, če tako odloči zdravnik.
In patients with atrial fibrillation, clopidogrel should be given as a single daily dose of 75 mg. ASA (75-100 mg daily) should be initiated and continued in combination with clopidogrel (see section 5.1). 
Bolniki z atrijsko fibrilacijo morajo klopidogrel dobivati v enem dnevnem odmerku 75 mg. ASA (75-100 mg na dan) je treba uvesti in nadaljevati v kombinaciji s klopidogrelom (glejte poglavje 5.1).
Plavix 75 mg film-coated tablets Clopidogrel should be given as a single daily dose of 75 mg. 
Plavix 75 mg filmsko obložene tablete Klopidogrel se mora dajati kot enkratni dnevni odmerek 75 mg.
PVC/PVDC/Aluminium or all aluminium perforated unit-dose blister packs in cardboard cartons containing 50x1 film-coated tablets. 
PVC/PVDC/aluminijast ali aluminijast perforirani pretisni omot za enkratni odmerek v kartonskih škatlah, ki vsebujejo 50x1 filmsko obloženo tableto.